Semin intervent Radiol 2021; 38(04): 445-452
DOI: 10.1055/s-0041-1732318
Review Article

Radioembolization of Secondary Hepatic Malignancies

Barbara Manchec
1   Miami Cardiac and Vascular Institute, Baptist Health South Florida, Miami, Florida
2   Miami Cancer Institute, Baptist Health South Florida, Miami, Florida
,
Nima Kokabi
3   Division of Interventional Radiology, Emory University School of Medicine, Atlanta, Georgia
,
Govindarajan Narayanan
1   Miami Cardiac and Vascular Institute, Baptist Health South Florida, Miami, Florida
2   Miami Cancer Institute, Baptist Health South Florida, Miami, Florida
,
Andrew Niekamp
1   Miami Cardiac and Vascular Institute, Baptist Health South Florida, Miami, Florida
2   Miami Cancer Institute, Baptist Health South Florida, Miami, Florida
,
Constantino Peña
1   Miami Cardiac and Vascular Institute, Baptist Health South Florida, Miami, Florida
2   Miami Cancer Institute, Baptist Health South Florida, Miami, Florida
,
Alex Powell
1   Miami Cardiac and Vascular Institute, Baptist Health South Florida, Miami, Florida
2   Miami Cancer Institute, Baptist Health South Florida, Miami, Florida
,
Brian Schiro
1   Miami Cardiac and Vascular Institute, Baptist Health South Florida, Miami, Florida
2   Miami Cancer Institute, Baptist Health South Florida, Miami, Florida
,
Ripal Gandhi
1   Miami Cardiac and Vascular Institute, Baptist Health South Florida, Miami, Florida
2   Miami Cancer Institute, Baptist Health South Florida, Miami, Florida
› Institutsangaben
Preview

Abstract

Cancer has become the leading cause of mortality in America, and the majority of patients eventually develop hepatic metastasis. As liver metastases are frequently unresectable, the value of liver-directed therapies, such as transarterial radioembolization (TARE), has become increasingly recognized as an integral component of patient management. Outcomes after radioembolization of hepatic malignancies vary not only by location of primary malignancy but also by tumor histopathology. This article reviews the outcomes of TARE for the treatment of metastatic colorectal cancer, metastatic breast cancer, and metastatic neuroendocrine tumors, as well as special considerations when treating metastatic disease with TARE.



Publikationsverlauf

Artikel online veröffentlicht:
07. Oktober 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA